Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hair loss side effect under scrutiny in fibroid drug study

NCT ID NCT06058728

Terminated Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study was designed to track hair loss in women with uterine fibroids who are taking the medication Oriahnn. Researchers planned to follow about 1,600 women for up to 24 months, using questionnaires and scalp photos to see how common hair loss is, when it starts, and if it goes away. However, the study was withdrawn before any participants were enrolled, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Oriahnn (elagolix with estradiol and norethindrone acetate)
What this could lead to
If successful, this study could help doctors better understand and manage hair loss as a side effect of Oriahnn in women with uterine fibroids.
What could go wrong
This is an observational study with no control group, so it cannot prove cause and effect. It was also withdrawn before enrolling any participants, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UTERINE FIBROIDS (UF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leiomyoma Menorrhagia uterine corpus leiomyoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UTERINE FIBROIDS (UF)

Contacts and locations

Locations

  • Dorsata /ID# 252675

    Arlington, Virginia, 22201-5330, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.